Unknown

Dataset Information

0

Protocol of a randomized controlled trial testing inhaled Nitric Oxide in mechanically ventilated patients with severe acute respiratory syndrome in COVID-19 (SARS-CoV-2).


ABSTRACT:

Introduction

Severe acute respiratory syndrome due to novel Coronavirus (SARS-CoV-2) related infection (COVID-19) is characterized by severe ventilation perfusion mismatch leading to refractory hypoxemia. To date, there is no specific treatment available for 2019-nCoV. Nitric oxide is a selective pulmonary vasodilator gas used as a rescue therapy in refractory hypoxemia due to acute respiratory distress syndrome (ARDS). In has also shown in-vitro and clinical evidence that inhaled nitric oxide gas (iNO) has antiviral activity against other strains of coronavirus. The primary aim of this study is to determine whether inhaled NO improves oxygenation in patients with hypoxic COVID-19. This is a multicenter randomized controlled trial with 1:1 individual allocation. Patients will be blinded to the treatment. Methods and analysis. Intubated patients admitted to the intensive care unit with confirmed SARS-CoV-2 infection and severe hypoxemia will be randomized to receive inhalation of NO (treatment group) or not (control group). Treatment will be stopped when patients are free from hypoxemia for more than 24 hours. The primary outcome evaluates levels of oxygenation between the two groups at 48 hours. Secondary outcomes include rate of survival rate at 28 and 90 days in the two groups, time to resolution of severe hypoxemia, time to achieve negativity of SARS-CoV-2 RT-PCR tests. Ethics and dissemination. The study protocol has been approved by the Investigational Review Board of Xijing Hospital (Xian, China) and by the Partners Human Research Committee (Boston, USA). Recruitment will start after approval of both IRBs and local IRBs at other enrolling centers. Results of this study will be published in scientific journals, presented at scientific meetings, reported through flyers and posters, and published on related website or media in combating against this widespread contagious diseases.

Trial registration

Clinicaltrials.gov. NCT04306393.

SUBMITTER: Lei C 

PROVIDER: S-EPMC7273302 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Protocol of a randomized controlled trial testing inhaled Nitric Oxide in mechanically ventilated patients with severe acute respiratory syndrome in COVID-19 (SARS-CoV-2).

Lei Chong C   Su Binxiao B   Dong Hailong H   Bellavia Andrea A   Fenza Raffaele Di RD   Fakhr Bijan Safaee BS   Gianni Stefano S   Grassi Luigi Giuseppe LG   Kacmarek Robert R   Morais Caio Cesar Araujo CCA   Pinciroli Riccardo R   Vassena Emanuele E   Berra Lorenzo L  

medRxiv : the preprint server for health sciences 20200524


<h4>Introduction</h4>Severe acute respiratory syndrome due to novel Coronavirus (SARS-CoV-2) related infection (COVID-19) is characterized by severe ventilation perfusion mismatch leading to refractory hypoxemia. To date, there is no specific treatment available for COVID-19. Nitric oxide is a selective pulmonary vasodilator gas used as a rescue therapy in refractory hypoxemia due to acute respiratory distress syndrome (ARDS). In has also shown <i>invitro</i> and clinical evidence that inhaled n  ...[more]

Similar Datasets

| S-EPMC7416469 | biostudies-literature
| S-EPMC2843768 | biostudies-literature
| S-EPMC4698022 | biostudies-literature
| S-EPMC2718405 | biostudies-literature
| S-EPMC3151218 | biostudies-literature
| S-EPMC7641257 | biostudies-literature
| S-EPMC5630225 | biostudies-literature
| S-EPMC7239076 | biostudies-literature
| S-EPMC2770191 | biostudies-literature
| S-EPMC4625637 | biostudies-literature